-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,…
GLENDALE, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- New users often do not know the difference between Delta 8 and…
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced…
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children…
Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tablORION CORPORATION PRESS RELEASE 5 SEPTEMBER 2022 AT 8.00 EEST Orion recalls Devisol Salmiakki dietary supplement from consumers…
Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2,…
REGULATED INFORMATION As a result of a technical error in the publication dated August 26, 2022, the Board of Directors…
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --…
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not…